Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Prepares For Cortrophin Launch

Company Anticipates FDA Approval By October

Executive Summary

US-based ANI Pharmaceuticals is looking to strengthen its leadership team and strategize a commercial approach for the launch of Cortrophin Gel, as it anticipates FDA approval by 29 October 2021. ANI reported a 2.4% increase in its generics business.

You may also be interested in...



What’s Next? Five Things To Look Out For In October

In October, Dr Reddy’s Laboratories and ANI Pharmaceuticals are among companies expecting to hear from the US Food and Drug Administration for key applications, as the annual joint conference of Medicines for Europe and the International Generic and Biosimilar medicines Association takes place in Athens, Greece.

ANI Transforms With Novitium And Sandoz Deals

US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches. 

ANI Picks Up US Dermatology Brands From Sandoz

ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel